Drug Trial Radar · NCT05341583
Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
202
Planned (sponsor's estimate)
Start
May 24, 2022
Primary completion
Jun 1, 2025
Study completion Jul 23, 2025
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or without chemotherapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
EnsartinibDrug
Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
PlaceboDrug
Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease free survival (DFS)Time frame: up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TianJin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.